Inhibiting Hv1 with the selective inhibitor YHV98-4 mitigates ETC deficiency in tauopathy, especially in complexes I and V, thereby reducing oxidative stress, rescuing mitophagy deficiency and restoring mitochondrial function. The gene discussed is HVCN1; the disease is tauopathy.